デフォルト表紙
市場調査レポート
商品コード
1720376

ジフテリアワクチン市場レポート:動向、予測、競合分析 (2031年まで)

Diphtheria Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031


出版日
発行
Lucintel
ページ情報
英文 150 Pages
納期
3営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.28円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

ジフテリアワクチン市場レポート:動向、予測、競合分析 (2031年まで)
出版日: 2025年04月25日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界のジフテリアワクチン市場の将来は、病院、クリニック、予防接種センター市場での機会により有望視されています。世界のジフテリアワクチン市場は、2025年から2031年までのCAGRが6.5%で、2031年までに推定80億米ドルに達すると予想されています。この市場の主な促進要因は、混合ワクチンの需要の増加、ジフテリアワクチン接種の重要性に対する意識の高まり、ジフテリアワクチン接種プログラムを推進する政府のイニシアチブの高まりです。

  • Lucintelの予測によると、ワクチンの種類別では、ジフテリア、破傷風、百日咳を予防するために広く使用されているDTaPワクチンが引き続き最大セグメントです。
  • 最終用途別では、病院がジフテリアの予防接種を受ける一般的な場所であるため、最大セグメントであり続けると思われます。
  • 地域別では、予防接種を受けていない人々の間でジフテリア症例が増加していること、主要メーカーが同地域に存在することから、北米が予測期間中に最も高い成長を示すと予想されます。

ジフテリアワクチン市場の戦略的成長機会

ジフテリアワクチン市場における戦略的成長機会は、技術進歩、公衆衛生ニーズの進化、世界のワクチン接種イニシアチブの拡大から生まれています。これらの機会を見極めることで、市場の大幅な成長と公衆衛生の向上が期待できます。

  • 新興市場への進出:ヘルスケアのニーズが高まる新興市場をターゲットにすることは、大きなチャンスとなります。これらの地域におけるワクチンへのアクセスと入手可能性を向上させることで、企業は市場へのリーチを拡大し、世界の疾病予防の取り組みに貢献することができます。
  • 新しいワクチン製剤の開発:改良型混合ワクチンや改良型アジュバントなど、新しいワクチン製剤の開発への投資は成長の可能性をもたらします。こうした技術革新は、ワクチンの有効性を高め、副作用を軽減し、公衆衛生のニーズの変化に対応することができます。
  • デジタルヘルス技術との統合:電子カルテやモバイルアプリなどのデジタルヘルス技術を活用することで、ワクチン接種の追跡や患者エンゲージメントを向上させることができます。この統合によりコンプライアンスが強化され、タイムリーなワクチン投与が可能になるため、市場全体の成長が促進されます。
  • ブースター投与プログラムの重視:ブースター投与プログラムの開発と推進により、免疫力の低下に対処し、長期的な予防効果を高めることができます。ブースター投与の重要性を強調することで、企業は需要を喚起し、さまざまな集団におけるワクチン接種率を高めることができます。
  • 世界な予防接種イニシアチブの強化:中低所得国におけるワクチンへのアクセスと公平性を向上させるため、世界のワクチン接種の取り組みや協力体制を支援することは、成長機会となります。こうした取り組みは世界保健目標に貢献し、ワクチンメーカーにとって新たな市場を創出します。

このような戦略的成長機会は、ジフテリアワクチン市場の潜在的拡大領域を浮き彫りにします。新興市場、新製剤、デジタル統合、ブースタープログラム、世界な取り組みに注力することで、企業は市場の動向を活用し、成長を促進することができます。

ジフテリアワクチン市場促進要因・課題

ジフテリアワクチン市場は、技術進歩、経済要因、規制問題など、さまざまな市場促進要因・課題の影響を受けています。これらの要因を理解することは、市場をナビゲートし、成長機会を活用する上で極めて重要です。

ジフテリアワクチン市場を牽引する要因は以下の通りです:

  • 技術進歩:改良型製剤や混合ワクチンなど、ワクチン技術における革新が市場成長の原動力となります。これらの進歩により、ワクチンの有効性、安全性、投与の容易性が向上し、より広範な採用と有効性に寄与しています。
  • 認識と需要の高まり:ジフテリアワクチン接種の重要性に対する意識の高まりと予防衛生対策に対する需要の増加が市場拡大の原動力となっています。公的教育や保健キャンペーンがワクチン接種率の向上や疾病予防の改善を促進しています。
  • 政府の支援と政策:資金援助、補助金、ワクチン接種ガイドラインの更新などの政府支援は、ワクチン開発と採用を促進しています。公衆衛生の向上と疾病予防を目的とした政策は、市場の成長に寄与しています。
  • 研究開発への投資:ワクチンの研究開発への多額の投資は、技術革新と新規ワクチンの導入を加速させます。政府、非公開会社、研究機関からの資金提供は、市場拡大を支援し、技術進歩を促進します。
  • 流通ネットワークの強化:ロジスティクスやインフラを含むワクチン流通網の改善により、アクセスやカバー率が向上します。効率的なサプライチェーンと流通システムは、より広範なワクチンの入手を促進し、市場の成長を支えます。

ジフテリアワクチン市場における課題は以下のとおりである:

  • 高い開発・製造コスト:ワクチンの開発と生産に関連する高コストは、市場成長の障壁となる可能性があります。これらのコストは、特に低所得地域や新興市場において、価格設定やアクセシビリティに影響を与えます。
  • 規制とコンプライアンスの問題:複雑な規制要件を乗り越え、地域によって異なる基準を確実に遵守することは困難です。規制上のハードルは、市場参入、製品の入手可能性、市場全体のダイナミクスに影響を与える可能性があります。
  • ワクチンの躊躇と受容:ワクチンの躊躇や安全性への懸念は市場成長に影響を与える可能性があります。一般市民の認識や誤った情報がワクチン接種率を妨げ、市場力学全体に影響を与える可能性があります。

これらの促進要因・課題は、成長機会を形成し市場ダイナミクスに影響を与えることで、ジフテリアワクチン市場に影響を与えます。技術の進歩、認知度の向上、政府支援、研究開発への投資、流通の強化が成長を促進する一方で、高コスト、規制上の問題、ワクチン接種へのためらいが課題となっています。ジフテリアワクチン市場で成功するためには、これらの要因に対処することが不可欠です。

目次

第1章 エグゼクティブサマリー

第2章 世界のジフテリアワクチン市場:市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 市場動向と予測分析 (2019年~2031年)

  • マクロ経済動向 (2019~2024年) と予測 (2025~2031年)
  • 世界のジフテリアワクチン市場の動向 (2019~2024年) と予測 (2025~2031年)
  • 世界のジフテリアワクチン市場:ワクチンの種類別
    • DTaPワクチン
    • DTワクチン
    • Tdapワクチン
    • Tdワクチン
  • 世界のジフテリアワクチン市場:最終用途別
    • 病院
    • クリニック
    • ワクチン接種センター
    • その他

第4章 地域別の市場動向と予測分析 (2019年~2031年)

  • 世界のジフテリアワクチン市場:地域別
  • 北米のジフテリアワクチン市場
  • 欧州のジフテリアワクチン市場
  • アジア太平洋のジフテリアワクチン市場
  • その他地域のジフテリアワクチン市場

第5章 競合分析

  • 製品ポートフォリオ分析
  • 運用統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略分析

  • 成長機会分析
    • 世界のジフテリアワクチン市場の成長機会:ワクチンの種類別
    • 世界のジフテリアワクチン市場の成長機会:最終用途別
    • 世界のジフテリアワクチン市場の成長機会:地域別
  • 世界のジフテリアワクチン市場の新たな動向
  • 戦略的分析
    • 新製品の開発
    • 世界のジフテリアワクチン市場の生産能力拡大
    • 世界のジフテリアワクチン市場における企業合併・買収 (M&A)、合弁事業
    • 認証とライセンシング

第7章 主要企業のプロファイル

  • AJ Vaccines
  • BIONET
  • GlaxoSmithKline
  • MassBiologics
  • Merck & Co
  • Panacea Biotech
  • Sanofi
  • Serum Institute India
  • Bharat Biotech
  • Meiji
目次

The future of the global diphtheria vaccine market looks promising with opportunities in the hospital, clinic, and vaccination center markets. The global diphtheria vaccine market is expected to reach an estimated $8 billion by 2031 with a CAGR of 6.5% from 2025 to 2031. The major drivers for this market are increasing demand for combination vaccines, rising awareness of the importance of diphtheria vaccination, and growing government initiatives to promote diphtheria vaccination programs.

  • Lucintel forecasts that, within the vaccine type category, the DTaP vaccine will remain the largest segment due to its wide usage to protect against diphtheria, tetanus, and pertussis.
  • Within the end use category, hospital will remain the largest segment as it's a common place where people get vaccinated against diphtheria.
  • In terms of regions, North America is expected to witness the highest growth over the forecast period due to rising cases of diphtheria among unvaccinated people and the presence of key manufacturers in the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Diphtheria Vaccine Market

Emerging trends in the diphtheria vaccine market reflect advancements in vaccine technology, evolving public health strategies, and changing global health dynamics. These trends are shaping how diphtheria vaccines are developed, distributed, and utilized.

  • Increased Use of Combination Vaccines: The trend toward using combination vaccines, such as DTP (Diphtheria, Tetanus, Pertussis), is growing. Combining vaccines simplifies immunization schedules and improves compliance by reducing the number of shots required. This approach also helps in maintaining high vaccination rates and comprehensive protection against multiple diseases.
  • Advancements in Vaccine Formulations: Innovations in vaccine formulations, including improved adjuvants and stabilization techniques, are enhancing vaccine efficacy and safety. New formulations aim to provide longer-lasting protection with fewer side effects, making vaccines more effective and easier to administer.
  • Focus on Booster Doses: There is increasing emphasis on administering booster doses to maintain long-term immunity. Updated vaccination schedules are incorporating more frequent boosters to address waning immunity and ensure continued protection against diphtheria, particularly in adults and high-risk populations.
  • Integration with Digital Health Technologies: Digital health technologies are being integrated into vaccination programs to improve tracking, reminders, and data management. Mobile apps and electronic health records are enhancing patient engagement and ensuring that individuals receive timely vaccinations and boosters.
  • Global Vaccination Initiatives: Global vaccination initiatives are focusing on improving diphtheria vaccination coverage in low- and middle-income countries. Efforts to address vaccine inequities and increase access to diphtheria vaccines are critical in preventing outbreaks and achieving global health goals.

These emerging trends are reshaping the diphtheria vaccine market by advancing vaccine technology, enhancing formulation efficacy, increasing the focus on boosters, integrating digital tools, and supporting global vaccination efforts. These factors contribute to more effective and accessible vaccination programs, ultimately improving public health outcomes.

Recent Developments in the Diphtheria Vaccine Market

Recent developments in the diphtheria vaccine market include technological advancements, policy updates, and increased focus on global vaccination coverage. These developments are driving improvements in vaccine efficacy, accessibility, and public health strategies.

  • Advancement in Combination Vaccines: Recent advancements include the development of more effective combination vaccines, such as the DTP vaccine, which combines diphtheria, tetanus, and pertussis protection in a single shot. This approach simplifies immunization schedules and improves vaccine uptake by reducing the number of required doses.
  • New Vaccine Formulations: Improved vaccine formulations have been introduced to enhance efficacy and reduce side effects. These formulations incorporate new adjuvants and stabilization technologies, providing better protection against diphtheria and ensuring longer-lasting immunity.
  • Enhanced Vaccination Guidelines: Many countries, including the United States and Germany, have updated their vaccination guidelines to include more frequent booster doses. These updates aim to address waning immunity and ensure continued protection, particularly in high-risk groups and older adults.
  • Expansion of Vaccine Access: Efforts to expand vaccine access in underserved regions, such as rural India and low-income countries, have been strengthened. New distribution networks and public health campaigns are improving vaccine availability and coverage, helping to prevent diphtheria outbreaks.
  • Integration of Digital Tools: The integration of digital health tools into vaccination programs is enhancing tracking, reminders, and data management. Mobile apps and electronic health records are being used to improve vaccination compliance and ensure timely administration of doses.

These recent developments are driving progress in the diphtheria vaccine market by advancing technology, improving formulations, updating guidelines, expanding access, and integrating digital tools. These factors contribute to more effective vaccination programs and better public health outcomes.

Strategic Growth Opportunities for Diphtheria Vaccine Market

Strategic growth opportunities in the diphtheria vaccine market are emerging from advancements in technology, evolving public health needs, and expanding global vaccination initiatives. Identifying these opportunities can lead to significant market growth and improved public health outcomes.

  • Expansion into Emerging Markets: Targeting emerging markets with growing healthcare needs presents a significant opportunity. By improving vaccine access and availability in these regions, companies can expand their market reach and contribute to global disease prevention efforts.
  • Development of New Vaccine Formulations: Investing in the development of new vaccine formulations, such as enhanced combination vaccines or improved adjuvants, offers growth potential. These innovations can increase vaccine efficacy, reduce side effects, and meet evolving public health needs.
  • Integration with Digital Health Technologies: Leveraging digital health technologies, such as electronic health records and mobile apps, can improve vaccination tracking and patient engagement. This integration enhances compliance and ensures timely administration of vaccines, supporting overall market growth.
  • Focus on Booster Dose Programs: Developing and promoting booster dose programs can address waning immunity and improve long-term protection. By emphasizing the importance of booster doses, companies can drive demand and enhance vaccination coverage in various populations.
  • Strengthening Global Vaccination Initiatives: Supporting global vaccination initiatives and collaborations to improve vaccine access and equity in low- and middle-income countries presents growth opportunities. These efforts contribute to global health goals and create new markets for vaccine manufacturers.

These strategic growth opportunities highlight potential areas for expansion in the diphtheria vaccine market. By focusing on emerging markets, new formulations, digital integration, booster programs, and global initiatives, companies can capitalize on market trends and drive growth.

Diphtheria Vaccine Market Driver and Challenges

The diphtheria vaccine market is influenced by various drivers and challenges, including technological advancements, economic factors, and regulatory issues. Understanding these factors is crucial for navigating the market and leveraging growth opportunities.

The factors responsible for driving the diphtheria vaccine market include:

  • Technological Advancements: Innovations in vaccine technology, such as improved formulations and combination vaccines, drive market growth. These advancements enhance vaccine efficacy, safety, and ease of administration, contributing to broader adoption and effectiveness.
  • Increased Awareness and Demand: Growing awareness of the importance of diphtheria vaccination and increased demand for preventive health measures are driving market expansion. Public education and health campaigns are promoting higher vaccination rates and improving disease prevention.
  • Government Support and Policies: Government support, including funding, subsidies, and updated vaccination guidelines, encourages vaccine development and adoption. Policies aimed at improving public health and disease prevention contribute to market growth.
  • Investment in Research and Development: Significant investment in vaccine research and development accelerates innovation and the introduction of new vaccines. Funding from governments, private companies, and research institutions supports market expansion and drives technological progress.
  • Enhanced Distribution Networks: Improvements in vaccine distribution networks, including logistics and infrastructure, enhance access and coverage. Efficient supply chains and distribution systems facilitate broader vaccine availability and support market growth.

Challenges in the diphtheria vaccine market are:

  • High Development and Production Costs: High costs associated with vaccine development and production can be a barrier to market growth. These costs impact pricing and accessibility, particularly in low-income regions and emerging markets.
  • Regulatory and Compliance Issues: Navigating complex regulatory requirements and ensuring compliance with varying standards across regions can be challenging. Regulatory hurdles can affect market entry, product availability, and overall market dynamics.
  • Vaccine Hesitancy and Acceptance: Vaccine hesitancy and concerns about vaccine safety can impact market growth. Public perception and misinformation may hinder vaccination rates and affect overall market dynamics.

These drivers and challenges impact the diphtheria vaccine market by shaping growth opportunities and influencing market dynamics. Technological advancements, increased awareness, government support, investment in R&D, and enhanced distribution drive growth, while high costs, regulatory issues, and vaccine hesitancy present challenges. Addressing these factors is essential for success in the diphtheria vaccine market.

List of Diphtheria Vaccine Companies

Companies in the market compete based on product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies, diphtheria vaccine companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the diphtheria vaccine companies profiled in this report include-

  • AJ Vaccines
  • BIONET
  • GlaxoSmithKline
  • MassBiologics
  • Merck & Co
  • Panacea Biotech
  • Sanofi
  • Serum Institute India
  • Bharat Biotech
  • Meiji

Diphtheria Vaccine by Segment

The study includes a forecast for the global diphtheria vaccine market by vaccine type, end use, and region.

Diphtheria Vaccine Market by Vaccine Type [Analysis by Value from 2019 to 2031]:

  • DTaP Vaccine
  • DT Vaccine
  • Tdap Vaccine
  • Td Vaccine

Diphtheria Vaccine Market by End Use [Analysis by Value from 2019 to 2031]:

  • Hospitals
  • Clinics
  • Vaccination Centers
  • Others

Diphtheria Vaccine Market by Region [Analysis by Value from 2019 to 2031]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Diphtheria Vaccine Market

There is increasing coordination for vaccinations and new health challenges, due to which the diphtheria vaccine market is making remarkable improvements. The current shifts are determined by the advancement of technologies, the revision of vaccination policies, and the changing epidemiology. In the major market regions such as the USA, China, Germany, India, and Japan considerable progress has been made in vaccine development, policy revisions, and diphtheria public health strategies.

  • United States: In the United States particularly, in the diphtheria vaccine market, recent changes have been listed as the improvement of the DTP (Diphtheria, Tetanus, Pertussis) combination vaccine and its wider use in adult booster doses. In developing countries there is emphasis in including diphtheria as part of routine childhood vaccines as well as enhance the surveillance systems of the vaccine. Reports from the CDC indicate that the guidelines have been adjusted over time to account for new strains.
  • China: There has been progress in increasing diphtheria vaccination coverage in China especially on the primary doses and booster doses. Recent developments are reasons such as new vaccines that have been developed and activities like improved transportation of the available vaccines. Furthermore, the China's government has redoubled health education campaigns to promote diphtheria vaccination among children and adults.
  • Germany: Germany has updated its vaccination guidelines to include more robust recommendations for diphtheria boosters, especially for older adults and travelers. Recent developments also focus on refining vaccine formulations to increase efficacy and reduce adverse reactions. The country is leveraging advancements in vaccine technology and research to enhance its diphtheria vaccination program and integrate it with broader immunization strategies.
  • India: In India, there has been significant progress in expanding diphtheria vaccination coverage, particularly in rural and underserved areas. Recent developments include the roll-out of improved vaccine formulations and increased efforts to boost vaccination rates through public health campaigns and mobile vaccination units. The Indian government is also working to strengthen its immunization infrastructure and ensure better access to vaccines across the country.
  • Japan: Japan has recently updated its diphtheria vaccination schedule to include more frequent booster doses, particularly for older adults and individuals at higher risk. Advances in vaccine technology and formulation are also being integrated into Japan's vaccination programs. The Japanese government continues to focus on public education and awareness campaigns to improve vaccine uptake and prevent outbreaks.

Features of the Global Diphtheria Vaccine Market

Market Size Estimates: Diphtheria vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Diphtheria vaccine market size by vaccine type, end use, and region in terms of value ($B).

Regional Analysis: Diphtheria vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different vaccine types, end uses, and regions for the diphtheria vaccine market.

Strategic Analysis: This includes M&A, new product development, and the competitive landscape of the diphtheria vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M&A, and more.

This report answers the following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the diphtheria vaccine market by vaccine type (DTaP vaccine, DT vaccine, Tdap vaccine, and Td vaccine), end use (hospitals, clinics, vaccination centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Diphtheria Vaccine Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

  • 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
  • 3.2. Global Diphtheria Vaccine Market Trends (2019-2024) and Forecast (2025-2031)
  • 3.3: Global Diphtheria Vaccine Market by Vaccine Type
    • 3.3.1: DTaP Vaccine
    • 3.3.2: DT Vaccine
    • 3.3.3: Tdap vaccine
    • 3.3.4: Td vaccine
  • 3.4: Global Diphtheria Vaccine Market by End Use
    • 3.4.1: Hospitals
    • 3.4.2: Clinics
    • 3.4.3: Vaccination centers
    • 3.4.4: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

  • 4.1: Global Diphtheria Vaccine Market by Region
  • 4.2: North American Diphtheria Vaccine Market
    • 4.2.1: North American Market by Vaccine Type: DTaP Vaccine, DT Vaccine, Tdap vaccine, and Td vaccine
    • 4.2.2: North American Market by End Use: Hospitals, Clinics, Vaccination centers, and Others
  • 4.3: European Diphtheria Vaccine Market
    • 4.3.1: European Market by Vaccine Type: DTaP Vaccine, DT Vaccine, Tdap vaccine, and Td vaccine
    • 4.3.2: European Market by End Use: Hospitals, Clinics, Vaccination centers, and Others
  • 4.4: APAC Diphtheria Vaccine Market
    • 4.4.1: APAC Market by Vaccine Type: DTaP Vaccine, DT Vaccine, Tdap vaccine, and Td vaccine
    • 4.4.2: APAC Market by End Use: Hospitals, Clinics, Vaccination centers, and Others
  • 4.5: ROW Diphtheria Vaccine Market
    • 4.5.1: ROW Market by Vaccine Type: DTaP Vaccine, DT Vaccine, Tdap vaccine, and Td vaccine
    • 4.5.2: ROW Market by End Use: Hospitals, Clinics, Vaccination centers, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Diphtheria Vaccine Market by Vaccine Type
    • 6.1.2: Growth Opportunities for the Global Diphtheria Vaccine Market by End Use
    • 6.1.3: Growth Opportunities for the Global Diphtheria Vaccine Market by Region
  • 6.2: Emerging Trends in the Global Diphtheria Vaccine Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Diphtheria Vaccine Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Diphtheria Vaccine Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: AJ Vaccines
  • 7.2: BIONET
  • 7.3: GlaxoSmithKline
  • 7.4: MassBiologics
  • 7.5: Merck & Co
  • 7.6: Panacea Biotech
  • 7.7: Sanofi
  • 7.8: Serum Institute India
  • 7.9: Bharat Biotech
  • 7.10: Meiji